まとめ
胸痛患者のイソソorbide dinitrate (ISDN) に対する耐性は,薬物の吸収が減少するのではなく,循環器の反応が低下することを意味します. 応答の回復は,耐性が逆行可能であり,ISDN代謝産物を含む可能性があることを示唆しています.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- 慢性的な安定性アンギナには,循環器の反応の効果的な管理が必要です.
- イソソルビド二酸化窒素 (ISDN) は,一般的な抗性薬である.
- ISDNに対する耐性は,長期的な有効性を制限する可能性があります.
研究 の 目的:
- 慢性的な安定した心痛の患者におけるイソソorbide dinitrate (ISDN) の循環反応と血濃度を調査する.
- ISDN.に対する耐性の発達と逆転性を評価する.
- ISDNの許容性を支える潜在的なメカニズムを探求する.
主な方法:
- 安定したアンギナを持つ10人の患者は,言語下ISDNを受けた.
- 口服によるISDN療法 (15時間ごとに6mg) は48時間投与された.
- 循環反応とプラズマISDNレベルは,コントロール,耐性,離脱期に測定されました.
- プラセボの置換は,可逆性を評価するために使用されました.
主要な成果:
- 言語下ISDNは当初,血圧の有意な低下を引き起こした.
- 口服ISDNの48時間後に,血管抑制剤の反応は著しく低下し,耐性を示しました.
- 許容性は,プラセボへの切り替えから21時間以内に回復しました.
- プラズマISDN濃度は,耐性状態では低下しなかったので,生体利用可能性が原因ではないことを示唆しています.
結論:
- 胸痛患者におけるイソソorbide dinitrateに対する耐性は,循環器の反応が弱まっていることが特徴です.
- 許容性は,薬剤の生物利用性の低下または排出の加速によるものではない可能性が高い.
- ISDN メタボリートの蓄積は,耐性につながる可能性があります.
- 耐性の可逆性は,治療調整の可能性を示唆しています.
関連する概念動画
01:14Time Course of Drug Effect
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...